All entries for: Design Therapeutics

November 5, 2025

Design Therapeutics

Neutral Outlook

Carlsbad, CA
51-200 employees

These actions and proposals, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions include, for example… directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products.

May 7, 2025

Design Therapeutics

Neutral Outlook

Carlsbad, CA
51-200 employees

For example, the Inflation Reduction Act (IRA) passed by Congress authorizes the Secretary of the Department of HHS to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.

Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
Scroll to Top